Recent Highlights

Latest Articles

2 days, 11 hours ago

AstraZeneca under pressure after drug disappointment spacer

As the market edges higher, AstraZeneca is heading in the other direction following disappointing results for its cancer drug recentin. The experimental treatment failed in a late stage head to ... The Guardian - business - 9:28 a.m. Monday 8th March 2010 GMT View Article Related Articles Email to Friend

5 days, 3 hours ago

Xstrata gains ground as FTSE 100 jumps to 18 month high spacer

Mining and financial shares led the way as the FTSE 100 surged to an 18 month high, helped by a return of investors' appetite for risk, hopes for a solution ... The Guardian - business - 4:54 p.m. Friday 5th March 2010 GMT View Article Related Articles Email to Friend

Glaxo could face $6bn Avandia liability, says UBS spacer

GlaxoSmithKline could face a liability of up to $6bn following problems with its diabetes drug Avandia in the US, according to City followers of the company. Analysts at UBS said ... The Guardian - business - 11:24 a.m. Friday 5th March 2010 GMT View Article Related Articles Email to Friend

Abbott To Collaborate With GSK On Molecular Diagnostic Test To Select Candidate Patients For Future Skin Cancer Immunotherapy spacer

Abbott (NYSE: ABT) announced that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who ... Medical News Today - 8 a.m. Friday 5th March 2010 GMT View Article Related Articles Email to Friend

Commodity prices help push FTSE to a seven-week high spacer

THE LONDON REPORT BRITAIN’S leading shares gained 0.9 per cent yesterday, boosted by strength in miners and oils, banks and life insurers, as upbeat US data lifted Wall Street. At ... City A.M. - 12:46 a.m. Friday 5th March 2010 GMT View Article Related Articles Email to Friend

6 days, 18 hours ago

FTSE rises as commodities and financials set the pace spacer

THE LONDON REPORT BRITAIN’S leading shares gained 0.9 per cent yesterday, boosted by strength in miners and oils, banks and life insurers, as upbeat US data lifted Wall Street. At ... City A.M. - 1:53 a.m. Thursday 4th March 2010 GMT View Article Related Articles Email to Friend

6 days, 20 hours ago

Gentronix secures three-year Glaxo deal spacer

Manchester-based university spin-out Gentronix has secured a three-year agreement with GlaxoSmithKline (GSK) to provide its GreenScreen HC and BlueScreen HC genotoxicity assays for use by GSK in genotoxicity screening. Crain's Manchester Business - 11:54 p.m. Wednesday 3rd March 2010 GMT View Article Related Articles Email to Friend

Vivus's Qnexa Will Become Decision Resources' Clinical Gold Standard In 2013 For The Treatment Of Obesity spacer

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of obesity, Vivus's Qnexa (the phentermine/topiramate combination) will earn ... Medical News Today - 1 p.m. Wednesday 3rd March 2010 GMT View Article Related Articles Email to Friend

1 week, 5 days ago

GlaxoSmithKline PLC : GSK files its Annual Report 2 spacer

6:20 PM: (GSK) GSK files its Annual Report 2 Investegate - 6:22 p.m. Friday 26th February 2010 GMT View Article Related Articles Email to Friend

GlaxoSmithKline PLC : Total Voting Rights spacer

12:24 PM: (GSK) Total Voting Rights Investegate - 12:25 p.m. Friday 26th February 2010 GMT View Article Related Articles Email to Friend

1,201 articles match your search

News Volume and Sentiment

Chart News Volume
News Sentiment Positive Negative

Related Organizations

Related People

Related Locations

Related Publishers